SUMMARY
The research of Robert A. Wermers, M.D., involves the clinical and epidemiological aspects of metabolic bone diseases. This includes analysis of five decades of the epidemiology of primary hyperparathyroidism in Rochester, Minnesota.
Dr. Wermers studies the epidemiological aspects of thiazide-associated hyperparathyroidism and Paget's disease of bone in Rochester.
He explores the field of metabolic bone disease, with multiple projects in several different areas.
Focus areas
- Primary hyperparathyroidism. Dr. Wermers studies the management of primary hyperparathyroidism. This includes long-term surgical outcomes, different treatment management strategies and new localization techniques.
- Non-parathyroid hormone (PTH) associated hypercalcemia. Dr. Wermers studies non-PTH mediated hypercalcemia and new treatments for this disorder.
- Metabolic bone disease. Dr. Wermers focuses on the evaluation and treatment of ENPP1 deficiency, hypophosphatemic disorders, hypoparathyroidism and clinical trials in rare metabolic bone disorders.
- The effects of parathyroidectomy on:
- Depression.
- Mortality.
- Hypercalciuria and bone mineral density in primary hyperparathyroidism.
- Surgical management of primary hyperparathyroidism.
- Evaluation of normocalcemic primary hyperparathyroidism.
- Clinical features of adult hypophosphatasia.
- Evaluation and management of non-PTH medicated hypercalcemia with new treatments.
- Treatment of osteoporosis.
- Clinical features and management of ENPP1 deficiency. This is a genetic condition affecting minerals in the body.
Significance to patient care
Dr. Wermers researches the understanding of optimal clinical management of primary hyperparathyroidism. He also explains the natural history of this common disease.
Dr. Wermers expands the clinical knowledge of less common, but highly impactful, metabolic bone diseases, including changes in the CYP24A1 gene, hypophosphatemic disorders and ENPP1 deficiency.